Premium
Long‐Term Response to Topiramate in Patients with West Syndrome
Author(s) -
Glauser Tracy A.,
Clark Peggy O.,
McGee Kathy
Publication year - 2000
Publication title -
epilepsia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.687
H-Index - 191
eISSN - 1528-1167
pISSN - 0013-9580
DOI - 10.1111/j.1528-1157.2000.tb02180.x
Subject(s) - topiramate , dose , medicine , refractory (planetary science) , adverse effect , antiepileptic drug , anesthesia , pediatrics , epilepsy , psychiatry , physics , astrobiology
Summary: Purpose : The long‐term effectiveness of topiramate (TPM) was evaluated in children with West syndrome previously refractory to antiepileptic drug (AED) therapy. Methods : Children with infantile spasms who completed a pilot study were eligible to enter a long‐term extension phase in which the dosages of TPM and other AEDs could be adjusted to optimal response (maximum, 50 mg/kg/day TPM). The mean duration of long‐term therapy was 18 months in the 11 children who were followed; the mean TPM dosage was 29 mg/kg/day. Results : Eight (73%) children were continuing TPM therapy at the time data were analyzed; four (50%) children were spasm free, seven (88%) had experienced a ges;50% reduction in spasms, and three (38%) were able to achieve TPM mono‐therapy. Conclusions : TPM was well tolerated in that no patients discontinued because of adverse events. The response achieved with TPM during the pilot study was maintained in most children.